Pharmaceutical composition comprising refined indigo naturalis extracts and the use thereof

Patent metadata

Field	Value
Publication number	US-11116811-B2
Application number	US-202016745690-A
Country	US
Kind code	B2
Filing date	Jan 17, 2020
Priority date	Apr 9, 2015
Publication date	Sep 14, 2021
Grant date	Sep 14, 2021

Abstract

A refined Indigo Naturalis extract or Indigo-producing plant extract containing at least 65% (w/w) an indirubin derivative based on total weight of active ingredients is described. Also described are a pharmaceutical composition containing the refined extract, and the use of the pharmaceutical composition for treating or alleviating a disease or condition.

First claim

The invention claimed is:

1. A method of inhibiting proliferation or differentiation of keratinocytes, inhibiting infiltration of mononuclear cells into the dermis and epidermis, inhibiting vascular alteration resulting in hyperplastic blood vessels, or inhibiting upregulation of adhesion molecules on endothelia cells, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising an extract of Indigo Naturalis, wherein the extract comprises, relative to the total weight of the extract:
65% to 90% (w/w) indirubin;
0.1-15% (w/w) indigo; and
0.01-5% (w/w) tryptanthrin.

2. The method of claim 1 , wherein the method is for inhibiting proliferation or differentiation of keratinocytes.

3. The method of claim 2 , wherein the pharmaceutical composition comprises 0.002% to 0.077% (w/w) of the extract relative to the total weight of the pharmaceutical composition.

4. The method of claim 3 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

5. The method of claim 2 , wherein the extract further comprises 0.1-5% (w/w) tryptanthrin relative to the total weight of the extract.

6. The method of claim 5 , wherein the extract further comprises 0.1-5% (w/w) qingdainone relative to the total weight of the extract.

7. The method of claim 1 , wherein the method is for inhibiting infiltration of mononuclear cells.

8. The method of claim 7 , wherein the pharmaceutical composition comprises 0.002% to 0.077% (w/w) of the extract relative to the total weight of the pharmaceutical composition.

9. The method of claim 8 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

10. The method of claim 7 , wherein the extract further comprises 0.1-5% (w/w) tryptanthrin relative to the total weight of the extract.

11. The method of claim 10 , wherein the extract further comprises 0.1-5% (w/w) qingdainone relative to the total weight of the extract.

12. The method of claim 1 , wherein the method is for inhibiting vascular alteration resulting in hyperplastic blood vessels.

13. The method of claim 12 , wherein the pharmaceutical composition comprises 0.002% to 0.077% (w/w) of the extract relative to the total weight of the pharmaceutical composition.

14. The method of claim 13 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

15. The method of claim 12 , wherein the extract further comprises 0.1-5% (w/w) tryptanthrin relative to the total weight of the extract.

16. The method of claim 15 , wherein the extract further comprises 0.1-5% (w/w) qingdainone relative to the total weight of the extract.

17. The method of claim 1 , wherein the method is for inhibiting upregulation of adhesion molecules on endothelia cells.

18. The method of claim 17 , wherein the pharmaceutical composition comprises 0.002% to 0.077% (w/w) of the extract relative to the total weight of the pharmaceutical composition.

19. The method of claim 18 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

20. The method of claim 17 , wherein the extract further comprises 0.1-5% (w/w) tryptanthrin relative to the total weight of the extract.

21. The method of claim 20 , wherein the extract further comprises 0.1-5% (w/w) qingdainone relative to the total weight of the extract.

Assignees

• Galderma Sa

Inventors

• Chantalat Laurent
• Andres Philippe

Classifications

• A61K8/4953

  containing pyrimidine ring derivatives, e.g. minoxidil · CPC title

• A61K36/19

  Acanthaceae (Acanthus family) · CPC title

• A61K36/315

  Isatis, e.g. Dyer's woad · CPC title

• A61K8/492

  having condensed rings, e.g. indol · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title